Fatty Liver and Diabetes: Why One So Often Brings the Other
Yes — fatty liver and type 2 diabetes are tightly linked, and the link runs both ways. A global analysis of 49,419 people with type 2 diabetes found fatty liver in 55.5% of them, steatohepatitis in 37.3%, and advanced scarring in 17% of those with fatty liver. Fatty liver, in turn, roughly doubles the risk of developing diabetes. Every adult with type 2 diabetes deserves a liver fibrosis check.
— Dr Chetan Kalal, DM Hepatology, Gleneagles Hospital Mumbai
Key takeaways
- More than half of people with type 2 diabetes have fatty liver: 55.5% in a meta-analysis of 80 studies from 20 countries.
- Among people with type 2 diabetes, 37.3% had steatohepatitis (fatty liver with inflammation), the form that drives scarring.
- Fatty liver itself raises the risk of developing type 2 diabetes about twofold (hazard ratio 2.22 across 19 studies and nearly 300,000 people).
- Insulin resistance is the shared engine of both conditions, which is why diabetes accelerates liver scarring and why the treatments overlap.
- Normal liver enzymes do not rule out significant liver disease in a person with diabetes; a FIB-4 score and FibroScan do the screening.
- Weight loss remains the foundation of treatment; pioglitazone and semaglutide have shown benefit on liver biopsy in randomised trials.
Picture a composite of a patient I see most weeks: a 52-year-old businessman whose diabetologist noticed “grade 1 fatty liver” on an ultrasound and asked for an opinion. His sugars have been controlled on tablets for nine years. His liver enzymes are normal. He is, frankly, irritated to be sent to a liver specialist at all. Then his FibroScan reads well above 13 kPa — a value that, in fatty liver, sits in the range of cirrhosis.
That story is not unusual in my clinic at Gleneagles Hospital. Fatty liver in a person with diabetes is the commonest liver problem I see, and the one most often dismissed as harmless. This article explains why the two conditions travel together, why diabetes makes the liver more dangerous, how to find out where you stand, and what treatment actually works. If you have type 2 diabetes, it is written for you — and for the doctor who looks after your sugars.
How common is fatty liver in people with diabetes?
Very. The largest global estimate comes from a 2019 meta-analysis in the Journal of Hepatology by Younossi and colleagues, pooling 80 studies from 20 countries and 49,419 people with type 2 diabetes. Fatty liver was present in 55.5%. Of the ten studies that looked for steatohepatitis — fatty liver with active inflammation and cell injury — the pooled prevalence was 37.3%. And among people with both diabetes and fatty liver, 17% already had advanced fibrosis.
Put plainly: in a room of six people with type 2 diabetes, three or four have fat in the liver, two may have steatohepatitis, and one could be heading towards cirrhosis without a single symptom.
The disease now carries a new name. In 2023 the international liver societies replaced “NAFLD” with MASLD — metabolic dysfunction-associated steatotic liver disease — precisely to put metabolic problems such as diabetes at the centre of the definition. I explain the full picture of the condition on my fatty liver page.
Why the link runs both ways
The common driver is insulin resistance. When muscle and fat tissue stop responding properly to insulin, the pancreas pumps out more of it, fat cells release fatty acids into the blood, and the liver both receives more fat and makes more of its own. A fatty liver, in turn, becomes resistant to insulin itself and keeps releasing glucose into the blood when it should stop. Each condition feeds the other.
That is why fatty liver is not merely a consequence of diabetes — it is also a warning of it. In a 2018 Diabetes Care meta-analysis of 19 studies covering 296,439 people followed for a median of five years, those with fatty liver had a 2.22-fold higher risk of going on to develop type 2 diabetes. The risk was higher still in people whose fatty liver was more severe. If you have fatty liver and normal sugars today, your HbA1c deserves a yearly check.
Indians carry a particular disadvantage here. We tend to store fat around the abdomen and in the liver at lower body weights than Europeans, which is why I regularly see fatty liver and diabetes in people who do not look overweight at all. A normal BMI is not reassurance.
Why diabetes makes fatty liver more dangerous
Diabetes is one of the strongest predictors that fatty liver will progress from simple fat to inflammation, then to scarring, cirrhosis and, in some, liver cancer. The 2024 European guidelines produced jointly by the liver, diabetes and obesity societies (EASL-EASD-EASO) identify type 2 diabetes as a key reason to look actively for advanced fibrosis rather than waiting for symptoms.
The trap is that this progression is silent. Liver enzymes (ALT, AST) are often normal even in advanced disease, and ultrasound “grades” describe fat, not scarring — a grade 1 report tells you nothing about fibrosis, as the businessman above discovers. I discuss what ultrasound grades do and do not mean in a separate article on grade 2 fatty liver.
| Finding | What it tells you | What it does not tell you |
|---|---|---|
| Ultrasound “fatty liver, grade 1–3” | Fat is present | Whether there is scarring or cirrhosis |
| Normal ALT and AST | No marked active inflammation at that moment | That the liver is healthy — advanced fibrosis can coexist |
| FIB-4 score (from age, AST, ALT, platelets) | A first screen for advanced fibrosis | An exact fibrosis stage |
| FibroScan (liver stiffness, kPa) | Likelihood of advanced fibrosis or cirrhosis | The cause of liver disease |
| Liver biopsy | Inflammation, fibrosis stage, other causes | Rarely needed for screening alone |
How to check your liver if you have diabetes
The EASL-EASD-EASO pathway is simple and cheap to start. First, a FIB-4 score, which any doctor can calculate from routine blood tests. If it is low, the risk of advanced fibrosis is low and the check is repeated periodically. If it is not low, the next step is elastography — usually a FibroScan, a ten-minute painless scan that measures liver stiffness. Only when results conflict or another cause is suspected do we consider a biopsy; I have compared the two in FibroScan vs liver biopsy.
Anyone whose stiffness suggests cirrhosis needs more than reassurance: six-monthly liver cancer surveillance, screening for varices, and a hepatologist’s follow-up. If that applies to you, my cirrhosis page explains what comes next.
Treatment: where the liver and the sugar meet
The good news is that what helps one condition usually helps the other.
Weight loss comes first. It is the most powerful liver treatment we have, and it improves blood sugar at the same time. In a one-year study by Vilar-Gomez and colleagues of 293 people with biopsy-proven steatohepatitis, those who lost 10% or more of their weight saw steatohepatitis resolve in 90% of cases and fibrosis regress in 45%. Diet does most of the work; I have set out a practical Indian plan in my fatty liver diet guide. Alcohol has no safe place in a liver that is already fatty.
Pioglitazone is an old, inexpensive diabetes drug that targets insulin resistance directly. In a randomised trial by Cusi and colleagues of 101 people with steatohepatitis and prediabetes or type 2 diabetes, 58% of those on pioglitazone achieved the main liver-improvement endpoint, and 51% had resolution of steatohepatitis, with benefits sustained over three years. The trade-off was weight gain — about 2.5 kg more than placebo — which is why it suits some patients and not others.
GLP-1 receptor agonists have changed the field. In the phase 3 ESSENCE trial of semaglutide in people with steatohepatitis and moderate or advanced fibrosis, steatohepatitis resolved without worsening fibrosis in 62.9% on semaglutide versus 34.3% on placebo, and fibrosis improved in 36.8% versus 22.4%. Semaglutide is now approved in India for this indication, and I cover who qualifies in my article on semaglutide for fatty liver. (Disclosure: I sit on advisory panels for Novo Nordisk and Eli Lilly, which make GLP-1-based medicines.)
The choice of medicine, dose and combination belongs to your doctors, who will weigh your sugar control, weight, heart and kidney health together. Please do not start or stop any diabetes medicine on the strength of an article — this one included.
What I tell every patient with diabetes
Ask for your FIB-4. If it is not low, get a FibroScan. Treat the ultrasound grade as a footnote, not a verdict. And if you have fatty liver with normal sugars, check your HbA1c every year, because the liver is often the first organ to show the metabolic trouble that diabetes later confirms.
For the businessman in that composite, the right path is not complicated: steady weight loss, a diabetes regimen chosen with the liver in mind, cirrhosis surveillance, and a repeat FibroScan to see the stiffness come down. None of it happens unless someone first refuses to call a fatty liver harmless.
Frequently asked questions
Can fatty liver cause diabetes?
Fatty liver is strongly associated with developing type 2 diabetes. In a meta-analysis of 19 studies and nearly 300,000 people, those with fatty liver had about twice the risk (hazard ratio 2.22) of developing diabetes over a median of five years. Insulin resistance links the two.
How many people with diabetes have fatty liver?
About 55% worldwide, according to a meta-analysis of 49,419 people with type 2 diabetes. Around 37% had steatohepatitis, and 17% of those with fatty liver had advanced fibrosis.
My liver tests are normal — can I still have liver damage?
Yes. ALT and AST are often normal even in advanced fibrosis. People with type 2 diabetes should have a FIB-4 score and, if it is not low, a FibroScan to check for scarring.
Which diabetes medicines help fatty liver?
Pioglitazone and the GLP-1 receptor agonist semaglutide have both improved steatohepatitis on liver biopsy in randomised trials. The right choice depends on your overall health and should be made with your doctors; weight loss remains the foundation of treatment.
Can fatty liver be reversed if I have diabetes?
Often, yes. Losing 7–10% of body weight can reduce liver fat and inflammation and may improve early scarring, while also improving blood sugar control. Established cirrhosis needs specialist follow-up.
Book a consultation with Dr Chetan Kalal at Gleneagles Hospital, Mumbai — call +91 83294 76669 or use the appointment form on this site. International and NRI patients may request a teleconsultation.
References
- Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol. 2019;71(4):793–801. PMID 31279902. doi:10.1016/j.jhep.2019.06.021
- Mantovani A, Byrne CD, Bonora E, Targher G. Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis. Diabetes Care. 2018;41(2):372–382. PMID 29358469. doi:10.2337/dc17-1902
- Cusi K, Orsak B, Bril F, et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann Intern Med. 2016;165(5):305–315. PMID 27322798. doi:10.7326/M15-1774
- Sanyal AJ, Newsome PN, Kliers I, et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025;392(21):2089–2099. PMID 40305708. doi:10.1056/NEJMoa2413258
- Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149(2):367–378. PMID 25865049. doi:10.1053/j.gastro.2015.04.005
- European Association for the Study of the Liver, European Association for the Study of Diabetes, European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines on the management of MASLD: executive summary. Diabetologia. 2024;67(11):2375–2392. PMID 38869512. doi:10.1007/s00125-024-06196-3
